Highly Potent Active Pharmaceutical Ingredients (HPAPI)
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020. HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines. Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry. Network and learn from leading professionals such as: CHAIR FOR 2020 - Justin Mason-Home, Director, HPAPI Project Services Limited KEY SPEAKERS INCLUDE: Pascal Michoux, Vice President, Global EHS Teva api & Biologics, teva API Italy William Hawkins, Manager Occupation Toxicology, GsK Brian Edwards, Chair, Pharmaceutical Human Factors Group, CIeHf Thomas Adam, Head of GQA Chemical APIs, Bayer AG Ildikó Ziegler, QA Manager, Gedeon Richter Francois D’Hooge, ADC Project Manager, Gamamabs Pharma Andreas Schreiner, Head of Validation, Novartis FEATURED HIGHLIGHTS:
- Explore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective
- Gain better understanding of human factors and ergonomics aspects and their role in improving production performance with the Chartered Institute of Ergonomics and Human Factors
- Deep dive into the oncology market and ADC production, the main driver of the HPAPI industry
- Learn what it takes to create a safety company culture and how to better train your employees on risk perception
View the full agenda: www.highlypotentapi.com/pharmaphorumwl Additional Contact Info: T: +44 (0) 20 7827 6164 E: nhoward@smi-online.co.uk
